Fed Circuit refuses to revive Parkinson’s disease patent

13-04-2023

Staff writer

Fed Circuit refuses to revive Parkinson’s disease patent

JHVEphoto / Shutterstock.com

Precedential decision upholds lower court’s earlier finding Patent at heart of the dispute covers treatment patch for Parkinson’s.


Federal Circuit, UCB, Teva, Actavis, Mylan, generics, patent infringement, ANDA, Parkinson’s disease,

LSIPR